TPXimpact Holdings PLC (TPX) — Investment Research Note

Executive summary

TPXimpact is a UK-listed digital transformation services firm (~90% public-sector, ~66% Central Government) that has just completed a three-year turnaround, taking adjusted EBITDA margin from ~3% (FY23) to 11.0% (FY26) while cutting net debt to £4.2m 2026-04 FY trading update. Revenue has been essentially flat over the cycle (£78.1m FY26 vs £84.3m FY24, with a dip to £77.3m in FY25 due to UK election/spending-review disruption) but profit conversion, cash generation and the balance sheet are materially better. The single most important point today is that the share price has already 5×'d over the past twelve months (16.75p → 86p) so the turnaround is now largely in the price — the debate is no longer "is this a going concern?" but "what growth rate justifies today's ~14–17× adj EPS multiple?".

Fair value estimate

• Fair value range: 70p – 100p per share → implied market cap £65m – £93m.
• Methodology: blended forward multiple. On FY26 adj EBITDA of £8.6m and net debt £4.2m 2026-04 FY trading, TPX trades at ~9.1× EV/EBITDA. I apply 8–10× EV/EBITDA to a modest FY27 progression to ~£9.5m (mid-single-digit revenue growth on a much bigger backlog with £122m new wins, plus a further ~50–100bps margin expansion) → EV £76–95m → equity £72–91m → 77–98p. Cross-check on adj EPS: FY26 adj diluted EPS looks set at ~4.5–5.0p (H126 was 1.7p on a stronger H2 skew) → 15–18× multiple gives 68–90p. Mid-point ~85p.
• Vs current 86p (mcap £74.9m): essentially in line.
• Absolute upside/downside: roughly 0% to mid (range −19% to +16%).

Sector context

Sector classification confirmed: Technology / IT Services — specifically a UK-focused digital transformation and Government-services consultancy. Quality/growth/leverage profile is now in line with typical peers (post-turnaround), whereas 18 months ago it was clearly below. Comparable listed peers: Made Tech (MTEC) — closest public-sector digital pure-play; Netcall (NET) — public sector/low-code adjacent; historically Kin and Carta (now taken private) sat in the same bucket. TPX is smaller, less software-y, and more concentrated on UK Central Government than these peers.

Investment thesis

• Turnaround is real and evidenced in the numbers, not just narrative. Adj EBITDA margin has moved from 3% (FY23) to 5.5% (FY24) to 7.3% (FY25) to 11.0% (FY26), with net debt/EBITDA down to 0.5× — all delivered against a falling revenue base, so it is a genuine cost/mix story rather than operational leverage from growth 2026-04 FY trading update; 2025-12 interims.
• Order book has stepped up materially heading into FY27. New business secured of £122m in FY26, including DEFRA £39m, NHS England £22m (with £11m option), and an £11m HMLR uplift; committed revenue at H126 already covered ~90% of full-year projections 2026-02 Q3 trading update; 2025-12 interims. This gives visibility on returning to growth in FY27, which the current multiple implicitly requires.
• Balance sheet is now a strength, not a risk. Net debt of £4.2m against a £11m RCF (+£5.5m accordion, +£4m overdraft) and 0.5× leverage means covenant risk is remote; the July 2025 refinance runs 3+2 years 2025-12 interims, Note 5; 2026-04 FY trading. Post-turnaround the business now generates cash rather than consuming it.

Key risks

• Extreme customer/sector concentration. ~90% public sector, ~66% Central Government, top 10 = 71% of H1 revenue. A single UK spending-review cycle (as happened FY25) can knock 8–10% off revenue and requires immediate cost action 2025-02 Q3 revised outlook; 2024-11 interims.
• The stock has re-rated ahead of the fundamentals. Revenue grew just 1% in FY26 and margin expansion has done all the heavy lifting; to justify 86p the market implicitly needs sustained mid-single-digit-plus growth from FY27 on top of further margin gains. A stumble on either would compress the multiple sharply given the recent 5× move.
• History of goodwill write-downs and executive turnover. £14.5m goodwill impaired in FY24, £4.5m in FY25, £1.8m on Norway disposal — legacy of the M&A-rollup era 2024-11 interims; 2023-12 interims. CFO also changed mid-FY26 (Winters → Douglas), and auditors continue to flag "high degree of judgement" over remaining goodwill carrying values 2025-12 interims, Note 2.

Operating leverage

TPX is a people-services business — cost of sales is dominated by employee/contractor time (£25m on £36m of revenue at H126), which scales roughly linearly with revenue. Gross margin of 31.7% (FY26) is not high-fixed-cost like software; the improvement from 26% to 31.7% over three years came from mix (less contractor reliance, higher utilisation) rather than pure fixed-cost dilution. Where genuine leverage exists is below the gross-profit line: admin costs fell from £44.4m (FY24) to £31.3m (FY25) as headcount was cut ~10%, and central corporate/system costs are now roughly fixed. Rough incremental logic: at 32% GM and a broadly fixed £22–24m admin base, every £10m of extra revenue drops £3.0–3.2m of gross profit, most of which would flow to EBITDA — so a 15% revenue beat (£12m) could add ~£3.5m to adj EBITDA, a ~40% uplift. That is meaningful but not multiples-of-profit leverage; TPX will not turn into a software company 2026-04 FY trading; 2025-12 interims.

Value-trap signals

• Multi-year flat/declining top line (£84m → £77m → £78m).
• History of goodwill impairments and disposals at a loss (Norway, Questers, RedCortex writedown).
• Extreme public-sector concentration in a country where digital-transformation budgets are politically variable.
• Two changes of CFO in three years; founder-led M&A era ended messily. None of these are individually dispositive — the recent execution is genuine — but they explain why the market held the shares at ~16p a year ago.

Earnings vs. expectations

• FY23: Q3 trading update Jan 2023 was a material miss/downgrade (£80m rev vs £90m prior; EBITDA margin 2–3% vs 5–6%).
• H1 FY23 (Sep 2022): Board Changes trading update was a downgrade — FY23 guidance cut to £90m/£7.0–7.5m EBITDA; both CEO and CFO stepped down.
• FY24: Beat, revenue >£84m vs £80–85m guide, margin in middle of range.
• FY25: Miss on revenue (down 8–10% vs prior "modest growth"), but Adj EBITDA margin beat — landed at £5.6m vs revised consensus £4.9m 2025-05 trading update.
• FY26: Beat and raise cycle — Q3 upgrade (Feb 2026) took EBITDA guidance to "not less than £7m"; FY26 came in at £8.6m vs consensus £7.1m 2026-04 FY trading. The pattern: misses were revenue-driven and market-related; recent beats are cost-discipline-driven. Track record is mixed — clearly better in the past 12 months.

Conviction

3 / 5 (moderate). Anchors: (1) FY26 numbers are freshly disclosed, clean, and consistent across three trading updates; (2) the business model (public-sector services on time & materials / framework contracts) is straightforward to value using multiples; (3) balance sheet is simple and well-disclosed. Caveats: (1) the appropriate exit multiple is highly sensitive to what growth rate you assume for FY27+, which is not yet visible in reported numbers (only 1% in FY26); (2) history of goodwill write-downs makes reported book values less trustworthy.

View: fair — the stock has already priced in the turnaround.